by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single [Read More]
Category: Research and Developments
AMD Report From ARVO 2011
by Dan Roberts It is important to note at the outset of this report that patients are highly respected across the professional board for their willingness to act as pioneers in the ongoing research. Our participation in clinical trials is greatly appreciated by the researchers. That having been said, here are latest updates on research [Read More]
Summary of Research and Developments in Macular Degeneration, 2010-2011
by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything [Read More]
Encapsulated Cell Technology (ECT)–A New Drug Delivery System
by Dan Roberts Updated March 30, 2015 A means of delivering drugs into the retina on a time release basis is being developed and proven safe and effective. It is achieved by a method called Encapsulated Cell Technology (ECT), being tested by Neurotech SA with support from the National Eye Institute (NEI), Bethesda, Maryland. A [Read More]
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]